Drug
Idelalisib
Idelalisib: highest development phase Phase 2, developed by Gilead Sciences. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Idelalisib NCT02590588 | Phase 2 | Amyloidosis |
| Idelalisib NCT02258529 | Phase 2 | Follicular Lymphoma |
Latest
No recent events.
Follow Idelalisib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.